Reasons for Healthcare Use Before Onset of Multiple Sclerosis: A Nationwide Matched Cohort Study in Sweden
European Journal of Neurology · 2025-12 · 32 (12)
DOI: 10.1111/ene.70464 ↗At a glance
Kohortenstudie in European Journal of Neurology, published online on 2025-12-08. Written by Ali Manouchehrinia and 6 co-authors. Institution: Karolinska Institutet, Stockholm, Sweden. Major MEDLINE topics: Multiple Sclerosis, Patient Acceptance of Health Care, Hospitalization. Cited 2 times so far (Crossref); 31 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Multiple Sclerosis Society, MS Canada.
Abstract (original language)
Background
Evidence suggests signs and symptoms may emerge years before the clinical onset of multiple sclerosis (MS). We investigated secondary healthcare use and medication dispensations before MS onset.
Methods
Using linked administrative data, we analyzed a neurologist‐diagnosed MS clinical cohort and an algorithm‐defined administrative cohort in Sweden (2001–2019). People with MS (PwMS) were matched to up to five non‐MS comparators by sex, birth year, residency location, and residency duration before the index date (clinical: symptom onset; administrative: first MS/demyelinating diagnosis code). Annual outpatient visits and hospitalizations by diagnosis codes across 19 years pre‐index, and dispensed medications by anatomical and therapeutic classifications across 14 years pre‐index were compared.
Results
The clinical cohort included 7604 PwMS and 37,974 matched comparators (median age at symptom onset = 35.5; 68.5% females). In the 5 years pre‐index, outpatient visits were 11%–73% higher among PwMS for disturbances of sense organs, nervous, musculoskeletal, digestive, and genitourinary systems, mental health/behavior, and ill‐defined symptoms/signs, with visits related to sense organs elevated up to 6 years. Hospitalizations were often elevated in the year pre‐index. Dispensations of nervous system‐related, musculoskeletal, blood‐related, metabolic, sensory, respiratory, and dermatological agents were elevated by 6%–22% in the 5 years pre‐index, with elevations in nervous system‐related and musculoskeletal agents extending up to 6–9 years pre‐index. Findings were similar in the administrative cohort with greater magnitudes and longer durations pre‐index.
Conclusions
We observed increased hospital, outpatient, and prescription utilization for multiple body systems 6–9 years pre‐MS onset. These patterns provide a more comprehensive picture of the MS prodrome.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Karolinska Institutet, Stockholm, Sweden.
- Alberta Health Services, Calgary, Canada.
- Faculty of Medicine (Neurology), University of British Columbia and The Djavad Mowafaghian Centre for Brain Health, Vancouver, British Columbia, Canada.
- Centre for Molecular Medicine, Karolinska Hospital, Stockholm, Sweden.
- ICES, Toronto, Ontario, Canada.
- School of Pharmacy, University of Waterloo, Waterloo, Canada.
ORCID profiles: Yinshan Zhao, Kyla McKay
Funding
- National Multiple Sclerosis Society
- MS Canada
Cite
APA
Manouchehrinia, A., Zhao, Y., Zhu, F., McKay, K., Maxwell, C., Marrie, R. A., & Tremlett, H. (2025). Reasons for Healthcare Use Before Onset of Multiple Sclerosis: A Nationwide Matched Cohort Study in Sweden. European Journal of Neurology, 32(12). https://doi.org/10.1111/ene.70464
Vancouver
Manouchehrinia A, Zhao Y, Zhu F, McKay K, Maxwell C, Marrie RA, et al. Reasons for Healthcare Use Before Onset of Multiple Sclerosis: A Nationwide Matched Cohort Study in Sweden. European Journal of Neurology. 2025;32(12). doi:10.1111/ene.70464
BibTeX
@article{Manouchehrinia2025,
author = {Manouchehrinia, Ali and Zhao, Yinshan and Zhu, Feng and McKay, Kyla and Maxwell, Colleen and Marrie, Ruth Ann and Tremlett, Helen},
title = {Reasons for Healthcare Use Before Onset of Multiple Sclerosis: A Nationwide Matched Cohort Study in Sweden},
journal = {European Journal of Neurology},
year = {2025},
volume = {32},
number = {12},
doi = {10.1111/ene.70464}
}
EUVIMED